Ensign Peak Advisors, Inc Eagle Pharmaceuticals, Inc. Transaction History

Ensign Peak Advisors, Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$26.42 - $47.12 $25,099 - $44,764	-950 Reduced 11.14%	7,577 $200,000
Q4 2021 Feb 11, 2022	SELL	$45.82 - $56.9 $384,429 - $477,391	-8,390 Reduced 49.6%	8,527 $434,000
Q2 2021 Aug 13, 2021	BUY	$36.86 - $44.5 $117,952 - $142,400	3,200 Added 23.33%	16,917 $724,000
Q1 2021 May 12, 2021	BUY	$40.32 - $50.97 $60,480 - $76,455	1,500 Added 12.28%	13,717 $573,000
Q1 2020 May 11, 2020	BUY	$34.37 - $60.07 $13,747 - $24,028	400 Added 3.38%	12,217 $562,000
Q4 2019 Feb 14, 2020	BUY	$54.32 - $64.31 $641,899 - $759,951	11,817 New	11,817 $710,000

8.6M

100

Ticker EGRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 13,015,900
Market Cap $7.81M
Description
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...

Get notified when there are updates to the investment portfolio of Ensign Peak Advisors, Inc, based on Form 13F filings with the SEC.

Stay updated on Ensign Peak Advisors, Inc with notifications on news.